T. Forcht Dagi at HLM Venture Partners to speak at the 2nd Diabetes Summit, April 19-20, 2012 Boston
T. (Teo) Forcht Dagi, Partner at HLM Venture Partners will give a featured presentation about "Funding Opportunities and What Venture Capitalists Seek in a Diabetes Investment" at the 2nd Diabetes Summit to be held on April 19-20, 2012 in Boston, MA by GTC.
- Boston, MA-NH (1888PressRelease) March 12, 2012 - Prior to joining HLM Venture Partners in 2006, Teo was a Managing Partner of Cordova Ventures in Atlanta and oversaw its life sciences and health care portfolio. Before joining Cordova Ventures, Teo served as Principal at Access Partners in Westport, CT.
Teo currently serves as a Board of Directors observer at MedVentive and TelaDoc. He was previously a director of 14 publicly traded and privately held companies including: Atherogenics, Argos Therapeutics, Axela Biosensors and Inhibitex. He also is on the advisory board of Vengrowth, Oxford Finance Corporation, and sits on the steering committee of the Program in Biomedical Entrepreneurship of the Massachusetts Institute of Technology.
With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
Come and join other diabetes experts at GTC's 2nd Diabetes Summit and hear key thought-leader's opinions to these questions and many more. This important meeting will be held on April 19-20, 2012 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
The 2nd Diabetes Summit will consist of 2 tracks:
5th Diabetes Drug Discovery and Development
2nd Diabetes Partnering & Deal Making
For more information, please visit www.gtcbio.com